Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2026-01-27

FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for DARZALEX FASPRO, submitted by Janssen Biotech, Inc. The approval updates the labeling for the drug, potentially …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))

Snippet

SUPPL AP for DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))